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Abstract: The results of recent outcome trials challenge hypotheses that tight control of both 
glycohemoglobin and blood pressure diminishes macrovascular events and survival among type 
2 diabetic patients. Relevant questions exist regarding the adequacy of glycohemoglobin alone 
as a measure of diabetes control. Are we ignoring mechanisms of vasculotoxicity (profibrosis, 
altered angiogenesis, hypertrophy, hyperplasia, and endothelial injury) inherent in current 
antihyperglycemic medications? Is the polypharmacy for lowering cholesterol, triglyceride, 
glucose, and systolic blood pressure producing drug interactions that are too complex to be clini-
cally identified? We review angiotensin–aldosterone mechanisms of tissue injury that magnify 
microvascular damage caused by hyperglycemia and hypertension. Many studies describe 
interruption of these mechanisms, without hemodynamic consequence, in the preservation of 
function in type 1 diabetes. Possible interactions between the renin–angiotensin–aldosterone 
system and physiologic glycemic control (through pulsatile insulin release) suggest opportuni-
ties for further clinical investigation.
Keywords: angiotensin-converting enzyme inhibitor, pulsatile insulin, diabetic nephropathy, 
cardiac autonomic neuropathy, podocytes, beta cells
Introduction
The Diabetes Control and Complications Trial (DCCT)1 established that multiple injec-
tions of insulin reduce microvascular complications in type 1 diabetes (Table 1). In the 
Captopril Study, angiotensin-converting enzyme (ACE) inhibition was demonstrated 
to preserve renal function in type 1 diabetes.2 Microvascular benefits from intensive 
glycemic management and ACE inhibition in type 2 diabetic patients have been 
reported in the UK Prospective Diabetes Study.3,4 Until recently, aggressive control 
of glycemia and blood pressure in type 2 diabetic patients was felt to be effective in 
the reduction of cardiovascular endpoints. Now that macrovascular endpoints have 
been found to be unresponsive to the highest doses of medications to lower glucose5 
and blood pressure,6 we must consider alternative research involving the preservation 
of renal function as an indirect way of preserving myocardial function.
Mechanisms by which kidney glomerular, interstitial, and vascular anatomy are 
injured include hypertension, inflammation, enhanced hemostasis, oxidative stress, 
diminished endothelial function, pathological angiogenesis, and accelerated fibrosis. 
High glucose and increased angiotensin have been shown to have additive pathological 
effects on renal tubules with accelerated fibrosis of the interstitium through enhanced 
expression of transforming growth factor (TGF)-β.7,8 Positive endpoint responses that 
cannot be explained by hemodynamic variations alone have been demonstrated.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Table 1 Advancing treatment approaches in type 1 diabetes in 
1993–1995
A. Diabetes control and complications trial
Multiple insulin injections were found to be associated with a lower  
incidence of diabetic nephropathy, retinopathy, and neuropathy
B. Captopril trial
Angiotensin-converting enzyme inhibitor was found to decrease the rate 
of loss of renal function, using the time to doubling of serum creatinine
C. Pulsatile insulin study14
Control of high and low blood glucose in type 1 diabetic patients was  
found to be improved beyond use of the DCCT protocol 7 days/week  
by use of the DCCT protocol 6 days/week + intravenous infusions  
of insulin in pulses 1 day/week. Each patient was his/her own control. 
This study did not address long-term complications
D. Orthostatic hypotension15
Improved lifestyle with stabilization of locomotion through diminution  
of this neurological complication when pulsatile insulin was added  
1 day/week to the DCCT protocol 6 days/week. Each patient was  
his/her own control
E. Hypertension16
Lower doses of antihypertensives required during 3-month rotations  
of the pulsatile infusion 1 day/week were added to the DCCT protocol  
6 days/week
Abbreviation: DCCT, Diabetes Control and Complications Trial.
The interruption of angiotensin–aldosterone mechanisms 
and optimal insulinization need further study. We call for 
prospective investigation of nonhemodynamic angiotensin 
effects that may alter intracellular insulin signaling with 
effects on renal and myocardial physiology.
Clinical trials
Losartan or enalapril prevented the onset of retinopathy by 
  photography, but did not alter the onset of nephropathy by 
  histology in type 1 diabetic patients.9 In type 2 diabetic patients, 
an improvement in albuminuria with angiotensin receptor block-
ade was associated with a reduction in markers for acceleration 
of inflammation and thrombosis, suggesting effects beyond 
blood pressure reduction.10 In type 1 diabetic patients, pulsatile 
use of insulin magnified the benefits of ACE inhibition.
Improved cardiac autonomic function and reversal of 
left ventricular hypertrophy were associated with improved 
glycemia in type 1 diabetic nephropathy patients. Renal 
and pancreatic transplantation has also been associated with 
reversal of left ventricular hypertrophy.
Although most studies demonstrate the prevention of a 
new appearance of retinopathy in type 1 diabetic patients 
treated with angiotensin-active medications, there is major 
inconsistency in the findings of protection from retinopathy 
progression for both type 1 and type 2 diabetic patients treated 
with angiotensin-active medications.
Kidney studies
In the Renin–Angiotensin–Aldosterone System (RAAS) 
Study, normotensive, normoalbuminuric type 1 diabetic 
patients with minimal evidence of retinopathy were observed 
for 5 years. A renal biopsy was done at baseline and repeated 
at 5 years. When compared with placebo, neither enalapril 
nor losartan had an effect on renal biopsy histology despite 
the fact that blood pressures were significantly lower than 
with placebo.9
The Irbesartan in Patients with Type 2 Diabetes 
and Microalbuminuria (IRMA2) Study (Table 2) found 
improvement in albuminuria associated with reduction 
in markers for inflammation, including C-reactive pro-
tein, interleukin-6 (IL-6), and fibrinogen.10 Patients were 
maintained on their usual diabetes treatment, which was 
associated with no significant decrease in advanced gly-
cation end products (AGE) concentration. Improvement 
of albuminuria without change in blood pressure over 52 
weeks was found in diabetic11 and nondiabetic12 kidney 
disease patients when spironolactone was added to a regi-
men of ACE inhibitor or ACE inhibitor plus angiotensin 
receptor blocker (ARB)12 as shown in Table 2. The latter 
study was associated with diminution of type 4 collagen, 
a marker of fibrosis. Improvement in AGE and glycohe-
moglobin A1c was associated with a reduction in elevated 
levels of fibrinogen and factor VII13 acute-phase reactants 
with hemostasis effects.
Table 1 summarizes the added benefit found with pulsatile 
insulin infusions for the stabilization of high and low blood 
glucose,14 postural hypotension,15 and supine hypertension16 in 
type 1 diabetic patients with emerging complications. Crossover 
studies demonstrated lower blood pressure medication require-
ments during pulsatile intravenous insulin infusions.16
A prospective randomized study of weekly pulsatile 
intravenous insulin infusions in type 1 diabetic patients with 
proteinuria and hypertension, including a control group on the 
multiple insulin injection (DCCT) protocol, was completed 
in several centers (Table 3). After 18 months, a statistically 
significant difference in progression of renal dysfunction was 
noted between the groups.17 For the pulsatile insulin group, 
it would take 15 years for the creatinine clearance (Ccreat) 
to fall from 50–60 mL/min to 10–15 mL/min compared with 
5 years utilizing the DCCT protocol without weekly pulsa-
tile infusions. This outcome could be expected to result in 
quality of life benefits in the trade-off of 1 day/week spent 
with insulin infusions versus multiple days per week with 
peritoneal or hemodialysis. The mechanism for added benefit International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Human studies: effects of nonhemodynamic angiotensin mechanisms
References Drug/patient Primary endpoint Comment
Persson et al10 Irbesartan 
Type 2 diabetes
Inflammatory markers 
decreased 
a. IL-6 
b. C-reactive protein 
c. Fibrinogen
Albuminuria decreased
Flammer et al44 Losartan versus atenolol 
Type 2 diabetes and 
hypertension
a.   Flow-mediated 
vasodilation decreased
b.   8-Isoprostane 
decreased with losartan, 
but not atenolol
8-Isoprostane is generated 
from membrane 
phospholipid by free radicals
Kramer et al45 Losartan 
Hypertension, no diabetes
a.   Platelet aggregation 
decreased after 8 h
b.   Endothelial cells 
(human)AT2-induced PDGF2-α +  
thromboxane blocked 
by incubation with EXP3179
Losartan metabolites: 
EXP3174 uses AT2 receptor 
EXP3179 no receptor 
Metabolism of losartan 
requires 8 h
Fortuno et al46 EXP3179 or losartan 
(but not EXP3174),  
irbesartan or quinapril, 
no diabetes
Human phagocytic 
mononuclear cells: 
a. NADPH oxidase 
b.   Protein kinase C 
expression inhibited
Expression of matrix 
metalloproteinase  
inhibited
Furumatsu et al11 Enalapril, losartan, and 
spironolactone, no diabetes
Albuminuria decreased 
over 1 year
Urine type 4 collagen 
decreased
Mehdi et al12 Lisinopril, spironolactone 
diabetes 
a. Type 2: 80% 
b. Type 1: 20%
Albuminuria 
decreased over 1 year
Table 3 Pulsatile insulin study: baseline17
A.   Randomized trial of DCCT protocol (control) versus DCCT protocol 6 days/week + pulsatile insulin (infusion group) 
1 day/week in type 1 diabetic patients with proteinuria, effect on progression of loss of renal function as measured by Ccreat
  1. Seventy-one patients seen every week
  2. Distribution: control (n = 34), infusion (n = 37)
B. ACE inhibitors preferred for blood pressure control
  1. Forty-five patients
  2. Distribution: control (n = 25) infusion (n = 20)
  3. Distribution: no ACE inhibitors: control (n = 9) infusion (n = 17), P = ns
C. Blood pressures (mmHg) by 24-h ambulatory method not significantly different at baseline, 52 weeks, and 78 weeks
Baseline Infusion group (n = 37) Control group (n = 34) P value
Systolic 133.6 ± 3.2 132.5 ± 2.6 0.79
Diastolic 77.8 ± 1.5 79.6 ± 1.7 0.44
52 weeks Infusion group (n = 37) Control group (n = 34) P value
Systolic 136.0 ± 2.7 133.2 ± 2.6 0.46
Diastolic 76.9 ± 1.8 78.7 ± 1.9 0.50
Baseline Infusion group (n = 23) Control group (n = 26) P value
Systolic 134.8 ± 4.7 134.5 ± 3.1 0.96
Diastolic 78.3 ± 1.8 80.4 ± 2.1 0.46
78 weeks Infusion group (n = 23) Control group (n = 26) P value
Systolic 131.6 ± 3.8 135.1 ± 3.4 0.49
Diastolic 74.7 ± 1.8 78.8 ± 2.2 0.17
Notes: Slopes of loss of Ccreat not significantly different at 52 weeks (n = 71); significantly different at 78 weeks (n = 49); did not change when the graph was drawn from 
52 to 78 weeks.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Table 4 Pulsatile insulin infusion: impact of ACE inhibition
A. Normal population 
1. Average rate of loss of Ccreat ∼1 mL/min/year
B. Type 1 diabetic nephropathy patients 
1. Prior to 2000 ∼15–25 mL/min/year 
2. Addition of pulsatile insulin to DCCT protocol
a. No ACE inhibition
    i. Control group loss = 5.3 mL/min/year
       ii. Infusion group loss = 5.2 mL/min/year
b. with ACE inhibition
    i.   Control group (n = 25) ∼8 ± 1 mL/min/year (52 weeks = 7.1;  
78 weeks = 8.9 mL/min/year)
       ii.   Infusion group (n = 20) ∼0.8 ± 0.2 mL/min/year (52 weeks = 0.96;  
78 weeks = 0.60 mL/min/year)
  iii. P values: unpaired t-test: 52 weeks ,0.11; 78 weeks ,0.02
  iv. wilcoxon rank sum test: 52 weeks ,0.20; 78 weeks ,0.01
C.   Mean arterial pressure for patients with highest slope of loss 
of Ccreat baseline, endpoint
1.   DCCT protocol (control group, n = 10) 93.1 ± 2.3,  
94.8 ± 3.1 mmHg
2. Pulsatile Iv (infusion group, n = 10) 91.8 ± 2.0, 91.3 ± 2.5 mmHg
D.   Mean arterial pressure for patients with lowest slope of loss 
of Ccreat baseline, endpoint
1.   DCCT protocol (control group, n = 10) 103.1 ± 3.0, 109.9 ± 
2.9 mmHg*
2. Pulsatile Iv (infusion group, n = 10) 100.7 ± 2.1, 99.9 ± 2.8 mmHg*
Note: *P , 0.05.
of pulsatile infusion could not be shown to involve any of 
the hemostatic, echocardiographic, ambulatory blood pres-
sure, or ambulatory electrocardiographic measures that were 
incorporated into the protocol.18
In light of newer angiotensin mechanisms in the research 
literature, our total data set,17 which has now become more 
relevant,19 can be summarized as follows (Table 4).
a.    The level of blood pressure was not lower with better 
preservation of renal function and was not higher with 
the faster loss of Ccreat in both study groups.
b.    Pulsatile infusion added no benefit to multiple injections 
in the absence of ACE inhibitors.
c.    The DCCT protocol group required significantly larger 
doses of ACE inhibitors (captopril, enalapril, fosinopril, 
lisinopril, and quinapril) compared with the pulsatile 
infusion group as predicted.16
d.    The combination of ACE inhibition with pulsatile infu-
sion was significantly better in preservation of Ccreat 
than ACE inhibition with multiple injections of insulin. 
When calculations were limited to individuals treated 
with ACE inhibitors, the estimated time for Ccreat to fall 
from 50–60 to 10–15 mL/min was ∼5 years for the DCCT 
protocol group versus ∼40 years for the DCCT + pulsatile 
infusion group.
Heart studies
The positive rationale for use of insulin therapy in type 2 
diabetic patients with normal renal function has recently been 
reviewed.20 Results from the United Kingdom   Prospective 
Diabetes Study (UKPDS)21 found both metformin and insu-
lin to be superior to sulfonylureas in the first 10 years with 
insulin superior to metformin in the second 10 years, using 
separate endpoints for death due to myocardial infarction, 
complications of diabetes mellitus, or a composite of all 
causes. Microvascular complications were also lowest in the 
insulin-treated group in the 20-year follow-up.
With left ventricular mass (LVM) increase, a long-term 
increased risk of heart failure and other morbid cardiovas-
cular events is observed. The prevalence of morbid events 
also increases as renal function decreases. LVM increases 
proportionately with pressure/volume increase, particularly if 
associated with calcification/stenosis of the cardiac valves, or 
the fluid overload of progressive renal dysfunction. Adverse 
ventricular remodeling therapy has focused on hemodynamic 
alteration. In our limited experience, however, lowering of 
glycated hemoglobin A1c concentration was associated with 
beneficial ventricular remodeling in diabetic nephropathy 
patients at equivalent blood pressures, suggesting a meta-
bolic nonhemodynamic mechanism22 (Table 5). Increased 
LVM in these patients would be seen as interstitial collagen/
fibrosis deposition superimposed on myocyte hypertrophy.23 
Reversal of diabetic cardiomyopathy (a definition restricted 
to individuals without coronary obstructive disease) was 
observed after successful renal transplantation.24 Elimination 
of fiber stretch may be a signal for downregulation of local 
angiotensin elaboration in the left ventricle, a subject of much 
research interest in both heart and kidney protocols.
A study of glycemia control in type 1 diabetic patients 
with nephropathy involved 23 patients with cardiac auto-
nomic neuropathy (CAN). Of these, 10 were classified as 
early autonomic neuropathy and 13 as advanced CAN. 
None of the patients were receiving β-blocker medications. 
Glycohemoglobin fell significantly at 3, 6, and 12 months 
in the early CAN group, but only at 6 months for advanced 
CAN. There were no changes in heart rate variability (HRV) 
for the advanced CAN group on 24-h ambulatory EKG over 
the course of the study. There were statistically significant 
increases in several tests within the time and frequency 
domains for HRV, suggesting an improvement in parasym-
pathetic function over the course of 1 year in the early CAN 
group.25 Most of the patients were receiving ACE inhibitors. 
In this same study, an improvement in glycohemoglobin 
A1c was associated with a significant reduction in LVM.22 International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Table 5 Pulsatile insulin study: cardiac and autonomic neuropathic 
studies
A. Objective measures of autonomic nervous system function
1.   Heart rate variability (HRv) not different for DCCT protocol  
(control group at Joslin) versus pulsatile insulin (infusion group  
at Joslin)
2. Combining study groups at Joslin
  a.   Patients with early cardiac autonomic neuropathy: 
Significant fall in glycohemoglobin A1c at 3, 6, and 12 months 
Several measures in the time and frequency domains indicated  
improved parasympathetic function25
  b.   Patients with advanced cardiac autonomic neuropathy: significant  
fall in A1c at 6 months only. No measures of HRv changed  
significantly for the better, indicating no improvement in 
parasympathetic function
  c.   Patient subgroup with a significant decrease in A1c had a significant  
reduction of left ventricular mass (LvM) on echocardiogram.22  
Patients without a significant improvement in A1c did not have  
a significant lowering of LVM
  d.   There was a significant statistical relationship between coefficient  
of variation of the RR interval (CvNN) and LvM26
B. Subjective response to questionnaire27
1. Peripheral nerves
  a. Feet (numbness, tingling, burning, and other pain)
  b. Eye (visual blurring)
  c. Genital (sexual function)
2. Autonomic nervous system
  a. Gastrointestinal (diarrhea)
  b. Postural hypotension (imbalance)
3.   Positive responses in questions relating to nerve function correlated 
highly with positive responses in preservation of Ccreat
Patients who did not achieve a significant improvement in 
A1c% also did not have a significant loss of LVM despite 
similar blood pressure control. Variation of HRV by the 
coefficient of variation of the RR interval (CVNN) test was 
related to loss of excess LVM.26 A1c was related to both 
autonomic nerve function and LVM, so finding an associa-
tion between autonomic nerve function and LVM change 
was expected (Table 5).
A questionnaire was used to determine subjective neu-
rologic endpoints in the study groups. Patients who experi-
enced relative stability of Ccreat reported significantly fewer 
problems with visual blurring, postural imbalance, intestinal 
disturbance (diarrhea), sexual dysfunction, and peripheral 
neuropathic sensations (numbness, tingling, burning, and 
other pain).27 Although AGE may interfere with recovery 
from objective sensory neuropathy,28 improvement in plasma 
concentration did not discriminate those patients who had 
subjective neurological benefits from those who did not.27 
Intermittent visual blurring may be due to dysfunction 
of corneal nerves that can now be studied with confocal 
microscopy.29 Use of this technology has documented 
early regeneration of corneal nerves following pancreas 
transplantation.30
Eye studies
Diabetic Retinopathy Control Trial-Prevention (DIRECT-
Prevent 1) and Diabetic Retinopathy Control Trial-Protection 
(DIRECT-Protect 1) studies are two randomized, double-
shielded, parallel-design, placebo-controlled trials that 
studied the effect of the ARB candesartan in normotensive, 
normoalbuminuric type 1 diabetic patients without or with 
retinopathy, respectively. In DIRECT-Prevent 1, during 
4.7 years, the incidence of new retinopathy was significantly 
lower in the candesartan group.31 However, among patients 
with existing retinopathy (DIRECT-Protect 1), candesartan 
did not have a beneficial effect on progression,31 unlike results 
in the EURODIAB-controlled trial of lisinopril in insulin-
dependent diabetes (EUCLID) in which lisinopril decreased 
retinopathy progression in nonhypertensive patients who 
had type 1 diabetes with little or no   nephropathy.32 With 
regard to type 2 diabetic patients with mild to moderate 
retinopathy studied in the DIRECT-Protect 2 trial, cande-
sartan significantly promoted the regression of retinopathy,33 
as opposed to findings in the ADVANCE study in which 
perindopril–indapamide-based blood pressure lowering 
or intensive glucose control did not significantly reduce 
the incidence and progression of retinopathy.34 Although 
most studies demonstrate the prevention of the new appear-
ance of retinopathy in type 1 diabetic patients treated with 
  angiotensin-active medications, there is major inconsistency 
in findings of protection from retinopathy progression for 
both type 1 and type 2 diabetic patients treated with angio-
tensin-active medications.
ACE inhibition and blockade of angiotensin receptor 
have been studied in multiple centers with an emphasis on 
small vessel complications of retinal and renal circulations. 
The effect of blood pressure lowering was demonstrated 
in the UKPDS study in which there was not much differ-
ence in retinopathy outcomes between an ACE inhibitor 
(captopril) and a β-blocker (atenolol), as long as similar 
blood pressure control was obtained (average attained BP 
144/82, mean pressure 108 mmHg), suggesting that the 
origin of retinal benefits in newly diagnosed type 2 diabetic 
patients was hemodynamic.35 When compared with placebo, 
progression of retinopathy in the RAAS study was reduced 
by 65% with enalapril and by 70% with losartan. Blood 
pressures were significantly lower in the enalapril and 
losartan groups when compared with placebo.9 Confirmation 
of the relationship between microvascular complications, International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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markers of inflammation, and glycemia control can now be 
achieved through the use of computer-assisted intravitreal 
microscopy.36 Future studies with technology that is capable 
of quantifying macular edema37 by optical coherence tomog-
raphy and retinal neurodegeneration38 may be useful in the 
evaluation of treatments.
Use of the standard grading system established by the 
Early Treatment Diabetic Retinopathy Study (ETDRS)39 at 
the central reading center (University of Wisconsin, Madison, 
WI, USA) provided an adequate measure of objectivity in 
evaluating a subset (n = 57) of the Pulsatile Intravenous Insu-
lin Treatment Study.17 There were no statistically significant 
differences in the two insulin study groups with respect to 
changes in retinal grading, despite significant differences in 
objective renal and subjective neurologic function over the 
course of the study.40 Baseline blood pressure, glycohemo-
globin A1c, and use of ACE inhibitors were not statistically 
significantly different. This study was not powered to define 
an effect of pulsatile intravenous insulin on the progression 
of retinopathy. In this small study, when aggressive lower-
ing of glycemia in the total group was analyzed, it appeared 
that progression of retinopathy was associated with a higher 
degree of variability of A1c despite lower levels of A1c, 
although not meeting statistical significance.41 An effect 
of high degrees of A1c variability has been reported to 
adversely affect incidence and progression of nephropathy/
retinopathy in type 1 diabetes;42,43 however, in both instances, 
variability was highest when A1c was highest.
Research studies
Research studies in humans indicate that the protective effects 
on microvasculature from the ARB losartan are related to 
its minor metabolite, which does not block the angiotensin 
receptor. Instead, EXP3179 has anti-inflammatory, antiplate-
let aggregation and antioxidant properties not found in other 
ACE inhibitors or ARBs. In animal models, angiotensin 
receptor blockade and ACE inhibition have been found to 
have antifibrotic effects, related in part to their effect on 
profibrotic local RAAS in the kidney, heart, and eyes.
Human studies
A pathogenetic role of angiotensin 2 (AT2) in microvascular 
complications in which blood pressure was not the central 
issue came from a study of 13 type 2 diabetic patients treated 
in a randomized fashion with either atenolol or losartan.44 
Flow-mediated dilation (endothelial-dependent) via hypere-
mia increased significantly following losartan compared with 
atenolol (P = 0.01) despite similar blood pressure control. 
Levels of 8-isoprostane, a marker for oxidative stress, did 
not change with atenolol but decreased significantly with 
losartan. The rise in flow-mediated dilation versus the fall 
in concentration of 8-isoprostane was statistically significant 
(Table 6).
Losartan, an angiotensin receptor 1 (AT1) blocker, 
functions through its major metabolite, known as EXP3174. 
Its minor metabolite, EXP3179, has important physiologic 
effects not involving blockade of the AT1 receptor. In a study 
involving 28 subjects with normal renal function, losartan 
treatment was associated with a significant decrease in 
platelet aggregation and concentrations of prostaglandin F2-α 
(PGF2α). The same researchers treated human endothelial 
cells ex vivo with EXP3179, which has molecular homology 
with indomethacin, prior to treatment with the proinflamma-
tory agents (AT2, lipopolysaccharide), demonstrating inhibi-
tion of cyclooxygenase and arachidonic acid stimulation of 
platelet aggregation.45 Mononuclear cells from hypertensive 
subjects (n = 153) that were evaluated ex vivo through the use 
of EXP317946 demonstrated inhibition of superoxide genera-
tion by nicotine adenine dinucleotide phosphate (NADPH) 
oxidase. Levels of plasma matrix metalloproteinase were 
also suppressed. This antioxidant response could not be dem-
onstrated with an ACE inhibitor (quinapril), AT1 blockers 
(irbesartan and losartan), or EXP3174 (Table 6).
Reported functions of EXP3179 include cyclooxyge-
nase blockade (anti-inflammation), nitric oxide synthase 
stimulation (vasodilation), tumor necrosis factor inhibition 
(antiapoptosis), peroxisome proliferator-activated agonist 
response (protects proximal tubule from toxicity of fatty acids 
in nephrotic syndrome), and decreased platelet aggregation 
by collagen inhibition (diminishes thrombosis).
Animal models
Fibrosis of the kidney and heart has been studied in 
experimental animals with or without diabetes. Anti-
  angiotensin–aldosterone treatments have been found to 
interrupt fibrosis. In some instances, the impact occurred 
without change in blood pressure. The diabetic Akita mouse 
model was used to test ACE2, a homolog for ACE, and was 
found to be associated with a decrease in AT2 levels in the 
plasma and renal cortex.47 Urinary albumin and 24-h albumin 
excretion were significantly lower compared with untreated 
controls. Glomerular hypertrophy, basement membrane 
thickening, and mesangial matrix expansion with collagen 
and smooth muscle actin were significantly less prominent 
than observed in controls. Renal cortical expression of 
nicotine adenine dinucleotide (NAD) phosphate oxidase, International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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nitric oxide synthase oxidase, and protein kinase C was 
significantly lower in treated animals. These findings provide 
evidence that blockade of signals of inflammation and 
oxidative stress diminished renal interstitial and mesangial 
fibrosis in the Akita diabetic mouse (Tables 6 and 7).
Demonstration of the effect of AT2 on the cardiac 
fibroblast was undertaken in a newborn Wistar rat 
model (nondiabetic). Genes for fibronectin and collagen 
increased within 45 min, but TGF as a marker for extra-
cellular matrix remodeling did not rise until after 60 min 
Table 6 Treatment of angiotensin signaling in microangiopathic remodeling
Inflammation Hemostasis Oxidative stress Vasodilation Angiogenesis Fibrosis
A. Endothelial function
1. Human study
  a. Losartan: Flammer et al44 + + +
Type 2 diabetes
  b. Losartan: Kramer et al45 +
No diabetes
  c. EXP3179: Fortuno et al46 +
No diabetes
2. Animal study
  a. EXP3179: watanabe et al63 + +
No diabetes
  b. valsartan: Michel et al64 +
    Spironolactone +
No diabetes
B. Retinal function
1. Animal study
  a. Candesartan: Kim et al60 + +
  b. Fosinopril: Zheng et al58 +
  c. Enalapril: Kim et al57 +
  d. Candesartan: Fukumoto et al59 + + +
  e. valsartan: wilkinson-Berka et al61 +
    Spironolactone + +
C. Renal function
1. Human study
  a. Irbesartan: Persson et al10 +
  b.   Protein kinase C inhibitors:  
Gruden et al56  
Tyrosine kinase inhibitors  
Human mesangial cells: no diabetes
+
  c.   Enalapril, losartan, and  
spironolactone:  
Furumatsu et al11
Nondiabetic
 
 
+
2. Animal study
  a.   ACE2: Qudit et al47 
Akita diabetic mouse
+ + +
  b.   Quinapril: Blanco et al83  
Zucker obese rat
+ +
D. Cardiac function
1. Animal study
  a.   Enalapril: Ma et al49 
Losartan 
Sprague–Dawley rat
+ +
+ +
  b.   Trandolapril: Onozato et al50 
Eplerenone 
Dahl salt-sensitive rat
+ +
+ +
  c.   Quinapril: Nemeth et al51 
Spironolactone
+
+
Note: + indicates a favorable response in returning marker toward control level.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Table 7 Studies that specifically mention that blood pressure was 
not changed or in which there was no difference between study 
groups when anti-angiotensin treatments reversed mechanisms 
of diabetic microvascular complications
A. Alloxan diabetic dog
1.   Avendano et al:55 both aminoguanidine and enalapril prevented 
ventricular stiffness associated with pathologic glycation of collagen 
over 6 months. There were no significant differences in aortic 
pressure, ejection fraction, or heart rate compared with controls 
despite the increased pressure/volume relationship.  
The concentration of ventricular collagen increased in the alloxan 
diabetic animals whether they were treated with enalapril or 
aminoguanidine or not treated
B. Akita diabetic mouse
1.   Qudit et al:47 human recombinant angiotensin-converting enzyme  
2 (ACE2), carboxypeptidase that transforms AT2 into A 1–7 without 
changing the ‘slightly elevated’ blood pressure of this animal, which 
has high blood glucose
2.   Factors that did change after 4 weeks of treatment included 
improvement in increased
  a. Protein kinase C
  b. Nitric oxide synthase oxidase
  c. NADPH oxidase
  d. Albuminuria
  e. Thickening of glomerular basement membrane
  f. Enlargement of glomerular mesangium
  g. Genes for collagen and actin
C. Zucker obese rat
1. Blanco et al83
2. Quinapril
3. Endpoint
  a. Proteinuria
  b. Glomerular histology (nephrosclerosis)
  c. Interstitial histology (infiltrate)
of AT2 superimposed upon hypoxia.48 The investigators 
concluded that the combined influence of AT2 and hypoxia 
may promote remodeling of myocardial interstitial matrix 
even in the absence of diabetes.
Three additional animal models for fibrosis (glomeru-
losclerosis) have concentrated on relevant mechanisms 
although are unable to eliminate hypertension as a factor 
(Table 6). Two of the studies used 5/6 nephrectomy in 
the rat, and one employed the Dahl salt-sensitive hyper-
tensive rat. Mechanisms for fibrosis included increased 
plasminogen activator inhibitor,49 increased TGF-β 
(TGFB) + NADPH oxidase,50 and TGFB + collagen type 
4.51 In these three animal models, treatment included 
enalapril, losartan, or both;49 trandolapril, eplerenone, or 
both;48 and quinapril, spironolactone, or both.51 Glomeru-
losclerosis was reduced toward baseline with all of these 
therapies along with reversal of increased profibrosis 
mechanisms. Such studies are encouraging in that use of 
anti-angiotensin–aldosterone medications may prevent 
irreversible remodeling of the left ventricle. Chronic kidney 
disease models associated with deficiency of vitamin D52 
or vitamin D receptor53 demonstrate increased interstitial 
inflammation/fibrosis of the kidney52,53 or heart.54 Either 
losartan53 or 1,25-dihydroxyvitamin D54 may impede inter-
stitial fibrosis of the kidney53 or heart54 in chronic kidney 
disease models.
When alloxan diabetic dogs were observed for 6 months, 
with no significant differences in aortic pressure, heart rate, 
or ejection fraction compared with normal controls, an 
increase in myocardial collagen was found (Tables 7). This 
collagen was linked to AGE and associated with decreased 
end-diastolic volume and increased end-diastolic pressure 
(and could be prevented by either aminoguanidine or enal-
april), again suggesting a biochemical nonhemodynamic 
target.55
A local RAAS exists in both the kidney and heart. Tension 
to the glomerular mesangium increases expression of protein 
kinase C and vascular endothelial growth factor (VEGF), 
resulting in fibrosis of the kidney,57 eye, and heart.23
Mechanisms of microangiopathic remodeling as they 
relate to AT2 signaling in the retina are summarized in 
Table 6. A combination of reverse transcriptase polymerase 
chain reaction, immunohistochemistry, and Western blotting 
demonstrated increased expression of VEGF in the retina of 
streptozotocin diabetic (STZ) rats. Eight weeks of treatment 
with enalapril (10 mg/kg) prevented an increase in retinal 
VEGF expression.56 Increased VEGF expression both in 
the retina of STZ rats and in bovine retinal endothelial cells 
(BREC) exposed to hyperglycemia has also been demon-
strated. This increased VEGF expression was attenuated 
by an ACE inhibitor that is associated with a diminution in 
histologic markers for retinal vascular damage.58 This study 
showed the protective effect of perindopril on mitochondrial 
dysfunction-induced reactive oxygen species (ROS).57 The 
Tori rat, a model of spontaneous type 2 diabetes, was used 
to demonstrate that retinal expression of genes for both 
VEGF and NADPH oxidase were promoted by AT2, which 
was reduced by candesartan.59 This   RAAS-ROS connection 
via AT2 infusion was associated with increased expression 
of VEGF and a subunit of the ROS-generating NADPH 
oxidase;59 these increases in expression (Table 6). were attenu-
ated by treatment with the ARB candesartan. It was found that 
retinopathy in the STZ diabetic animal model was associated 
with vascular leakage and increased VEGF expression (Table 
6). Treatment with perindopril was able to reverse all of 
these abnormalities and restore the integrity of tight junction 
proteins that occlude the spaces between cells.60International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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An RAAS process was associated with inflammation, 
angiogenesis, and enhanced expression of NADPH oxidase in 
oxygen-induced retinopathy. Spironolactone and valsartan both 
prevented inflammation and angiogenesis.61 Because aldos-
terone inhibits nitric oxide synthase, spironolactone may have 
been helpful in promoting the generation of nitric oxide.62
The post-insulin receptor signal is conveyed to mito-
chondria via phosphoinositol 3-phosphate (PI3p), Akt, 
and adenosine monophosphate (AMP) with inhibition by 
AT2. This PI3p/Akt signal system operates in bovine aortic 
endothelial cells. Studies using losartan have shown that 
metabolite EXP3179 inhibits the angiotensin response, pro-
tects the receptor for VEGF, and therefore diminishes cellular 
death through apoptosis.63 In the mouse limb ischemic model, 
induction of neovascularization and VEGF protein are demon-
strated in aldosterone-treated animals and inhibited equally by 
spironolactone, valsartan, and antibody to VEGF64 (Table 6). 
Because aldosterone is instrumental in neovascularization 
of both the ischemic limb and the retina exposed to excess 
oxygen, the interactions of angiotensin/aldosterone, VEGF, 
and the insulin signal require further elucidation. Further 
research could be done on whether the new class of renin 
inhibitors might also exhibit nonhemodynamic synergy with 
pulsatile insulin release with microvascular benefits.65
Type 2 diabetes: glomerular 
podocyte and pancreatic β-cell 
undergo similar dysfunction
Ultrastructural studies of the podocyte and pancreatic β-cell 
reveal similarities in cytoskeletal proteins, such as nephrin, 
that are related to cell trafficking as well as to leveraging 
proteins in cardiac myocytes. Inflammatory effects of obesity 
interfere with efficient functioning of those proteins and 
thus interfere with the podocyte slit diaphragm and insulin 
release. Type 2 diabetes is characterized by increased size 
and disordering of the amplitude of pulsatile insulin release 
from β-cells and eventually by decreased size of the pulse, 
and may be related to a local angiotensin–aldosterone effect 
on somatostatin. The interruption of adequate delivery of 
glucose to the medullary thick ascending limb leads to   
injury from excess angiotensin–aldosterone. Future research 
may show that correction of excess angiotensin–aldosterone 
may help to reverse these effects.
Developments in researching the ultrastructure of the 
kidney epithelial cell podocyte, the pancreatic islet β-cell, and 
certain muscular structures have identified similar proteins 
through which the cytoskeleton provides leverage for timely 
functions. Resisting the excretion of albumin, enhancing the 
secretion of insulin, or relaxing a muscle appropriately after 
contraction requires proteins, some of which are structurally 
similar, that can function through attachment to the cytoskel-
etal protein actin. Electron microscopy of the β-cell has identi-
fied an actin latticework that is available for attachment.66
The cytoskeleton is no longer viewed as a capsule to 
prevent entry of bacteria and viruses. Actin filaments form 
polymers that have been described as a polygon on electron 
microscopy.67 Much is known about the β-cell, which mainly 
employs nephrin and syntaxin interaction with actin. The 
podocyte utilizes large numbers of cooperating proteins, 
among which are nephrin, NCK protein, podocin, and 
synaptopodin. When the extracellular portion of nephrin 
engages neighboring foot processes,68 the intracellular por-
tion engages actin to promote leverage (Table 8).
In both the podocyte and the β-cell, coordinated function 
is most critical after the intake of food. Efficient function of 
the nephron and the islets of Langerhans requires opening 
and closing of transit pathways. The β-cell has a cytoplasmic 
latticework66 ‘cell web’ that conducts vesicles of insulin to 
the outer cell membrane. The podocyte has efficient glucose 
absorption once the glucose transport (GLUT) apparatus has 
been conducted to the outer cell membrane. Both podocytes 
and β-cells have a vesicular-binding protein, VAMP (vesicle-
associated membrane protein), that associates with moving 
components and then separates as movement ends with docking 
at the plasma membrane. In the podocyte, nephrin and VAMP 
associate with GLUT protein vesicles that are then able to move 
to the plasma membrane with a signal from insulin.69 In the 
β-cell, nephrin and VAMP associate with insulin vesicles70 that 
are then able to move to the plasma membrane with the help of 
syntaxin71 and a signal from glucose (Table 8).
The effects of diabetes or obesity may inhibit the impact 
of nephrin and adiponectin. AGEs impede podocyte function 
by cross-linking of filaments of actin and associated lever-
age proteins, making it difficult to keep the foot processes 
of adjacent podocytes aligned. The receptor for AGE is 
colocalized with synaptopodin, one of the leverage proteins 
responsible for the retention of albumin.72 AGEs also acceler-
ate apoptosis of β-cells and podocytes by elaboration of an 
apoptosis effector protein.73
Podocyte chemistry has remote relationships to cardiac 
physiology. Nephrin is coexpressed with myocardin, a 
protein of both cardiac and smooth muscle origin. Other 
podocyte proteins (smoothelin and calponin) relate strictly 
to a smooth muscle origin. Through smoothelin, the podo-
cyte responds to AT2 by contraction in an actin-dependent 
manner74 (Table 8). Insulin resistance is associated with International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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inhibition of AMP kinase through increased protein concen-
tration of NOX4, an oxidase of NAD. Angiotensin-induced 
oxidative stress in heart failure may respond to the use of 
anti-angiotensin medications, such as receptor blockers. 
Telmisartan inhibits the oxidase of NADPH and promotes 
AMP kinase, which leads to more efficient generation of 
adenosine triphosphate (ATP). This same sequence occurs in 
the β-cell, which would otherwise experience a reduction in 
glucose-stimulated insulin secretion,75 and might also be at 
risk for apoptosis.76 Metformin enhances AMP kinase, which 
is protective in experimental models of β-cell apoptosis77 
and heart failure.78
Nephrin suppresses the inflammation cascade by 
inhibiting nuclear factor-κβ (NF-κβ), as does adiponectin, 
the adipokine most active in promoting the postreceptor 
insulin signal. Animal models of mutant nephrin79,80 or 
adiponectin knockout81 demonstrate that proteinuria is found 
to be reversible with restoration of functional nephrin or 
adiponectin (Table 8). Adiponectin inhibits NF-κβ through 
a cyclic AMP-  dependent pathway,82 the last major point in 
the insulin signal before activation of mitochondrial glucose 
oxidation80 (Table 8). The obese diabetic Zucker rat develops 
glomerulosclerosis and interstitial infiltrate. Glomerular 
nephrin is depleted. Quinapril, but not diltiazem, reversed 
all of these abnormalities without a change in blood pres-
sure83 (Table 6).
Insulinization utilizing pumps has been an immense 
step forward in glycemia control. Nevertheless, there is 
no method of physiological infusion of insulin in routine 
use. Insulin is secreted in pulses every 10 ± 2 min. It has 
been considered that the first phase of insulin secretion is 
the release of older granules that are already docked at the 
plasma membrane. The second phase of insulin secretion 
involves younger insulin vesicles bound to their intracyto-
plasmic protein carriers (nephrin and syntaxin) co-operating 
in propulsion through the transit pathway toward the plasma 
membrane (Table 8). Recent cellular research has suggested 
that under certain experimental conditions, the younger 
insulin granules from healthy human β-cells may be the 
first to be released in response to glucose.84 Both oral intake 
and intravenous infusion of 30 g of glucose increases the 
rate of pulsation by 40%, but the incretin effect with oral 
intake results in a 70% greater mass of insulin secreted in 
these same pulsations.85
The onset of type 2 diabetes is characterized by 
increased amplitude and disordering of the rhythm of insulin 
pulses. In later stages, as the size of the pulse decreases, 
the patient becomes insulin dependent. Several drugs 
increase the amplitude but do not change the rhythm of 
pulses: sulfonylurea,86 glucagon-like peptide,87 and sodium 
  salicylate.88 Decreases in pulse amplitude of insulin secre-
tion may occur as a result of catechol stimulation. A link 
between type 2 diabetes and pheochromocytoma has been 
described in patients with a genetic mutation, resulting 
in an increased number of α-2 adrenoreceptors with a 
decreased number of insulin granules docked at the β-cell 
plasma membrane.89 This could explain the observation of 
hyperglycemia during increased catecholamine expression 
as being related to increased glycogenolysis and decreased 
secretion of insulin pulses.90
Table 8 Nephrin functions in several tissues (kidney, pancreas, and possibly central nervous system)
Podocyte of kidney Pancreas β-cells
Anchors adjacent foot processes by extracellular domain through  
attachment to actin cytoskeleton by its intracellular domain68
Anchors intracellular filaments of actin cytoskeleton66,67
Requires assistance of other proteins (NCK, podocin, and syn  
protein family). Receptor for advanced glycated end products  
colocated with synaptopodin72
Requires assistance of syntaxin71 intracellularly in a way 
more closely cooperative than the functions of podocin and 
synaptopodin, where the leverage effect occurs extracellularly
Cooperates in translocation of glucose transporter protein vesicles 
across cytoplasm to dock at plasma membrane.69 Accompanied by vAMP, 
a protein that moves with other proteins that have taken the form of  
vesicles (granules). Process is critical for intake of fuel; insulin and  
adiponectin have a signaling role
Promotes translocation of insulin vesicles across cytoplasmic 
‘cell web’ to dock at plasma membrane. Accompanied by vAMP. 
Process critical for timely insulin secretion70
Inhibits nuclear factor-κβ (NF-κβ).82 Animal model of mutant nephrin79,80 
adiponectin knockout81 have elevated NF-κβ, proteinuria, glomerular 
pathology corrected with replacement of nephrin
AGEs cause apoptosis. AGEs also can cross-link actin filament 
to alter the timing and amplitude of insulin secretion73
Coexpressed with myocardin, a protein of both cardiac and smooth muscle  
origin. Other podocyte proteins (smoothelin and calponin) relate strictly  
to a smooth muscle origin. Through smoothelin, podocyte responds to  
angiotensin 2 by contraction in actin-dependent manner.74 Podocytes have  
similarities to pericytes of the central nervous system and retina
Angiotensin 2 provokes apoptosis through NADPH oxidase; 
prevented by telmisartan75International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Metabolic efficiency is improved by pulsatile hormonal 
delivery when compared with steady infusion91,92 (Table 9). 
The islets of Langerhans secrete glucagon,91 insulin,92 and 
somatostatin91 in a pulsatile fashion from the α-, β-, and 
γ-cells. There is general agreement that somatostatin acts as a 
governor of these cells through receptors on α- and β-cells,93 
preventing overwork to the point of exhaustion. β-cells also 
have local AT2-generating systems94 through angiotensin-
converting enzyme with receptors (AT1 and AT2) in place. 
Action on the β-cell angiotensin axis can be expected to affect 
metabolism of somatostatin, insulin, and glucagon. Studies 
of insulin secretion following infusion of AT2 in healthy 
volunteers have shown that pressor doses diminished levels 
of basal and glucose-stimulated oscillations. The regularity 
of insulin oscillation was not changed by AT2 infusion.95 We 
suspect that future studies will demonstrate that inhibition 
of excess angiotensin–aldosterone has widespread benefits 
in hormonal balance that may not be corrected simply with 
physiological insulinization.
Preservation of function in chronic glomerular disorders 
depends on remodeling of the interstitium. Disorders of 
blood supply or oxygen transfer, such as diabetes or sickle 
cell anemia, are associated with medullary papillary necrosis 
while the cortex is spared. The cortex can utilize fuels gener-
ated under stress,96,97 including ketones (β-hydroxybutyrate), 
fatty acids (palmitate), glycerol, triglycerides, glutamine, 
lactate, mannose, and fructose.97
Medullary energy production depends on anaerobic gly-
colysis in the thick ascending limb of the distal tubule where 
mitochondria exists. Energy for sodium/chloride transport 
against an interstitial gradient for water resorption in the 
collecting ducts depletes medullary reserves.98 As the renal 
medulla operates at lower levels of oxygen concentration/
consumption,99,100 hematocrit,101 and blood flow101 than the 
cortex, pulsatile insulin delivery may be critical. These obser-
vations pinpoint the renal medullary interstitium as a sus-
ceptible focus of injury from excess angiotensin–aldosterone 
when imperfect insulin supply occurs.
Individuals with type 1 diabetes are not exempt from the 
growing epidemic of obesity, which would be expected to 
add insulin resistance to insulin deficiency. In type 1 diabetic 
nephropathy patients treated with pulsatile insulin infusions, 
we have observed an increase in respiratory quotient (RQ) 
in every instance, indicating a direction of fuel oxidation 
away from β-oxidation of fatty acids to aerobic oxidation 
of glucose in mitochondria.102 In several patients, transitory 
elevations of RQ to .1.0 may have been the result of excess 
fuel with synthesis of fatty acid, leading to deposition of 
triglyceride, because diacylglycerol is also an endpoint of 
insulin action. Deposition of triglyceride may occur in the 
liver, adipose, muscle (skeletal and cardiac), and pancreas 
(β-cell). We have no experience with type 2 diabetic neph-
ropathy patients undergoing experimental use of pulsatile 
insulin infusion.
From these biological observations it can be speculated 
that glomerular and β-cells are injured in similar ways by 
mechanisms seen in uncontrolled hyperglycemia. There-
fore, treatments that eliminate these injury patterns may be 
expected to preserve the function of both the nephron and 
the islets of Langerhans. The function of the myocardium 
tends to improve in situations that are favorable to either the 
pancreas or the kidney. When the function of the myocardium 
has been improved, there is improvement in renal function.
Future potential interventions 
to control cellular metabolic 
derangement
Studies of the use of TNF-α inhibitors in rheumatologic 
disease suggest clinical (reduction of cardiac events) and 
laboratory evidence (improved HDL antioxidant capacity 
and endothelial responsiveness) for cardiovascular benefit.103 
A role of both TNF-α and IL-1 has been demonstrated in 
postinfarction human heart failure and isolated rat cardiac 
fibroblast. In both instances the process is augmented by 
angiotensin.104–106
Demonstration that RAAS activation, mechanical stretch, 
and myocardial injury stimulate production of TNF-α,107 
hydroxyl radicals, IL-1β, and NF-κβ has led to studies that 
Table 9 Pulsatile insulin secretion
A. Insulin secretion
1. Insulin is secreted ∼10 times/h85
2.   Hormones secreted in oscillations are more efficient than when 
equimolar amounts are tested by continuous infusion91–93
B. Islets of Langerhans
1. Glucagon and somatostatin secreted together at the same pace93
2. Insulin has a different cadence
C. Type 2 diabetes
1. Rhythm of insulin secretion disordered
2.   Amplitude increased at first, then after several years begins to 
decrease due to AT2 generated in islets94
D.   Drugs that increase amplitude, but do not change  
rate of oscillations
1. Sulfonylurea86
2. Glucagon-like peptide87
3. Sodium salicylate88
E. Drugs that decrease amplitude, but do not change secretion rate
1. Thiazide diuretic88
2. α-Adrenergic agonist89,90International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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demonstrate the possibility that the benefit of medications 
such as carvedilol108,109 and statins110 may be related not 
only to their effect on heart rate, blood pressure, and lipids 
but also to regulation of oxidative stress. Animal studies 
support TNF-α inhibition as a therapy for the reduction of 
oxidative stress, myocardial mitochondrial dysfunction, and 
apoptosis.111,112 Laboratory and clinical evidence additionally 
links TNF-α and oxidative stress to postmyocardial infarc-
tion progression to heart failure.113 Thiazolidinediones may 
enhance TNF-α induction of IL-1, and this may explain 
problems within this class of drugs.104
There are no clinical outcome studies involving inhibition 
of TNF-α in patients with diabetic nephropathy. The effect of 
both AT2114 and TNF-α115 on sodium potassium ATPase of 
the medullary thick ascending limb of the loop of Henle is to 
inhibit resorption of sodium and chloride. We have referred 
to this site in the renal medulla, which is critical for water 
preservation, as a potential site for injury in uncontrolled gly-
cemia with insulin deficiency/resistance.98 The oxidative stress 
that attacks the most vulnerable position in the renal medulla, 
where energy is required for transport of sodium chloride, has 
been shown to be overcome by candesartan/valsartan in type 
2 diabetes.116 Because this therapeutic process was associated 
with inhibition of expression of IL-6, there is a suggestion 
that future studies should involve a combination of therapy 
of ARBs with inhibitors of IL or TNF-α. A note of caution 
is required, however, due to reports of the development of 
immune glomerulonephritis in rheumatoid arthritis patients 
treated with etanercept, adalimumab, or infliximab.117
The primary focus for the preservation of cardiovascular, 
renal, and retinal integrity in diabetes has been related to 
RAAS activation, blood pressure, and glycemic control. 
Recent studies have demonstrated relationships between 
these factors and cellular signaling that may be additional 
targets for intervention. The goal is to alter rates of pro-
grammed cell death (apoptosis), oxidative stress, thrombosis, 
inflammation, and fibrosis. Given the impact of successes 
in the rheumatologic therapies, future research using these 
additional cellular targets may be worthwhile.
Conclusion
We have reviewed angiotensin–aldosterone mechanisms 
of tissue injury that magnify microvascular damage caused 
by hyperglycemia and hypertension. Many studies describe 
interruption of these mechanisms, without hemodynamic 
consequence, in the preservation of function in type 1 
diabetes. Possible interactions between the RAAS and 
physiologic glycemic control (through pulsatile insulin 
release) suggest opportunities for clinical research. Until 
we have better markers of risk for microvascular complica-
tions, therapy must be directed at minimizing variability of 
hemoglobin A1c.118
The results of recent outcome trials challenge hypotheses 
that tight control of both glycohemoglobin and blood pressure 
diminishes macrovascular events and survival among type 2 
diabetic patients. These results raise relevant questions. Is 
glycohemoglobin an adequate measure of diabetes control? 
Are we ignoring mechanisms of vasculotoxicity (profibrosis, 
altered angiogenesis, hypertrophy, hyperplasia, and endothelial 
injury) inherent in current antihyperglycemic medications? Is 
the polypharmacy for lowering cholesterol, triglyceride, glu-
cose, and systolic blood pressure producing drug interactions 
that are too complex to be clinically identified? Answers to 
these questions will most certainly improve our understanding 
of disease mechanisms and further refine therapies.
On the basis of our review of the literature, we suggest 
that these nonhemodynamic effects on renal, cardiac, and 
ocular microvasculature are as important, if not more so, 
as the hemodynamic effects of ACE inhibition and AT2 
receptor blockade. Although the macrovascular effects of 
uncontrolled hypertension and diabetes are clear, we are only 
now beginning to understand the microvascular complica-
tions. Answers to these questions will most certainly improve 
our understanding of disease mechanisms and allows us to 
further refine therapies, such as the interruption of local 
RAAS and use of pulsatile insulin to reduce proinflammatory 
and profibrotic forces. These therapies, in turn, will help to 
improve the lives of our patients.
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